First-time use of newer oral contraceptives and the risk of venous thromboembolism

This publication has 16 references indexed in Scilit:

• End of the line for “third-generation-pill” controversy?
  The Lancet, 1997
• Population-based study of risk of venous thromboembolism associated with various oral contraceptives
  The Lancet, 1997
• Oral contraceptives and thrombotic diseases: Impact of new epidemiological studies
  Contraception, 1996
• The increased risk of venous thromboembolism and the use of third generation progestagens: Role of bias in observational research
  Contraception, 1996
• Comments on Desogestrel and Gestoden (3rd Generation Progestogens) and the Incidence of Thromboembolism
  Hormone and Metabolic Research, 1996
• Are third-generation oral contraceptives safe?
  Human Reproduction, 1996
• Oral contraceptives and thrombotic diseases: Impact of new epidemiological studies
  Contraception, 1996
• Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease
  The Lancet, 1995
• Risk of idiopathic cardiovascular death and rionfatal venous thromboembolism in women using oral contraceptives with differing progestagen components
  The Lancet, 1995
• Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen
  The Lancet, 1995